At Medicor, we are always in search of promising new cancer therapies for our patients. We believe in collaborating with other physicians and sharing information for innovation, improvement of therapies and for the advancement of medical science. Below are a few of the prominent doctors and researchers with whom we have established ongoing relationships to increase our understanding and also share our knowledge of cancer therapeutics. They are listed alphabetically.
- Dr. Burton Berkson, USA
- Dr. Harold C. Clark and Dr. Mariella Clark, USA
- Dr. Isaac Eliaz, USA
- Dr. George Grant, Canada
- Dr. Ursula Jacob, Gemany
- Dr. Chul Jun Kim, S. Korea
- Dr. Young Ko and Dr. Peter Pedersen, USA
- Dr. Ken Matsumura, USA
- Dr. Vikas Sukhatme and Vidula Sukhatme, USA
Dr. Burton Berkson, MD
Founder and Director of the Integrative Medical Center, New Mexico, USA
www.drberkson.com
Dr. Akbar Khan with Dr. Burton Berkson at the OncANP conference in Carefree, AZ (April 2012)
Dr. Berkson is a pioneer in the use of integrated therapies for cancer and other illnesses. He is an expert in the use of the natural medicine alpha lipoic acid as a component of cancer therapy, along with low dose naltrexone, and has published the first case reports of human efficacy of these gentle medications in metastatic pancreatic cancer. A list of his publications can be found on Medline.
Dr. Harold C. Clark, MD and Dr. Mariela Clark, MD
Drs. Harold and Mariela Clarke run an innovative integrative medical practice in New Rochelle, New York, USA. They frequently collaborate with Dr. Ursula Jacob (see below).
Dr. Akbar Khan meeting with Drs. Harold and Mariela Clark in New York (Nov 2010)
Dr. Isaac Eliaz, MD
www.amitabhaclinic.com | www.dreliaz.org
Dr. Isaac Eliaz is a respected author, lecturer, researcher, product formulator, and clinical practitioner. He has been a pioneer in the field of integrative medicine since the early 1980s. Dr. Eliaz regularly participates in clinical studies and has been published in well-recognized, peer-reviewed journals.
He is also co-author of the world’s first research paper on intravenous use of dichloroacetate in cancer therapy.
Dr. Isaac Eliaz seated with Dr. Khan
Dr. George Grant, PhD
Dr. George Grant, PhD, IMD, DHS
www.academyofwellness.com
Dr. Grant is considered one of the Canadian authorities in integrative medicine. Dr. Grant is an expert in biofeedback, stress, anti-aging and natural pain management. He is the founder & CEO of the Academy Of Wellness. Dr. Grant enjoys a stellar academic career in research. He is a scientist, professor, chemist, toxicologist, nutritionist, biofeedback, stress management and a pain specialist. Dr. Grant has worked as a Senior Consultant for Health Canada, FDA and CDC. Dr. Grant has helped fortune 500 companies, non-profit organizations and Olympic athletes along with 5000 clients worldwide. He has over 100 published articles, conference presentations, book reviews and seven bestselling books.
Dr. Grant firmly believes in the Medicor philosophy of non-toxic cancer therapy, and that prevention is the best cure for cancer that we have today. We are honoured to work with him.
Dr. Ursula Jacob, MD
Founder and Medical Director of the “Dr. Ursula Jacob Dayclinic for Prevention and Regeneration”, Germany
www.doc-jacob.com
Dr. Akbar Khan meeting with Dr. Ursula Jacob in New York (Nov 2010)
Dr. Jacob is the founder and medical director of a private clinic in Germany that provides advanced cancer treatments, many of which are not available in North America. Treatments are based on a scientific, integrated and personalized approach. Her clinic became known worldwide after model and actress Farrah Fawcett traveled there for her own cancer treatment, and televised a documentary about her experience as a cancer patient.
Dr. Chul Jun Kim, MD
CEO Healing Garden Hospital, Seoul, Korea
Dr. Akbar Khan and Dr. Chul Jun Kim at the Medicor Office (Sept 2010)
Dr. Kim visited Medicor Cancer Centres in 2010 to discuss gentler cancer therapies for older patients who are poor candidates for harsh conventional therapies such as chemotherapy. While working with Dr. Khan and Dr. Andrews, he gained practical knowledge for the use of DCA and LDN, as well as various natural therapies.
Dr. Young Ko, PhD and Dr. Peter Pedersen, PhD
Dr. Young Ko and Dr. Peter Pedersen with Dr. Humaira Khan and Dr. Akbar Khan at the Medicor Office (Dec 2008).
Dr. Ko and Dr. Pedersen are professors at the Johns Hopkins University (Baltimore, Maryland, USA). They have conducted pioneering research into an exciting anti-cancer drug called 3-bromopyruvate in animal tumour models. Their research has demonstrated cures of liver cancer in rats though intra-tumoural injection and intra-arterial infusion of 3-BP with minimal toxicity to the animals. They are currently in need of support for ongoing research in humans. A list of their publications can be found on Medline.
Dr. Ken Matsumura, MD
Founder of the Berkeley Institute International and the Alin foundation.
www.berkeley-institute.com alinfoundation.com
Dr. Matsumura is a world-renowned scientist. He developed the HeartAlarm® Wristwatch that gives advanced warning against heart attacks, invented the bio-artificial liver, and invented the artificial pancreas which in collaboration with Johnson & Johnson, NASA invited onto the Space Shuttle. His bio-artificial liver is listed in several international websites as one of the top ten inventions of the past decade, along with YouTube® and iPAD®. His bio-artificial liver was honored by Time magazine as an Invention of the Year in 2001.
Dr. Matsumura discovered the breakthrough drug that eliminates serious side effects of cancer chemotherapy. By also protecting the immune system from destruction during chemotherapy, his new medications makes ordinary cancer drugs into powerful agents that have saved many terminal patients. The longest survivor is a lung cancer patient now living over 9 years without a trace of cancer. The next longest survivor, who had stage four breast cancer with non-eradicable liver metastasis, has also been living without cancer for 9 years.
Dr. Matsumura visiting the Medicor office in July 2013
A note from the Medical Director: Without the tireless efforts of Mr. Robert Curto (of Ft. Lauderdale, Florida) to connect various professionals in the field of cancer therapy, we would not have known of Dr. Matsumura and his remarkable achievements. Mr. Curto advised us of the existence of “SEF Chemo” (previously known as “ToxFree Chemo”) in 2007. This sparked our interest and we got in touch with Dr. Matsumura immediately. At the time, the therapy was being refined and Dr. Matsumura was not prepared to have it administered at our clinic. However, patience led to a call from Dr. Matsumura in the summer of 2013, indicating his willingness to permit the “SEF Chemo” program to expand to Toronto. We have now witnessed our first complete remission of incurable stage 4 cancer using this therapy (no evidence of cancer by CT scan, blood markers and circulating tumour cell count). Other patients are doing very well and hopefully are not far behind. Amazing results have been achieved in pancreatic cancer, lung cancer, cervical cancer, melanoma and breast cancer (all stage 4). A big thank you Robert!
bobbycurto@webtv.net
Dr. Khan meeting Mr. Robert Curto for the first time in Florida (May 2014)
Dr. Vikas Sukhatme, MD, PhD and Vidula Sukhatme
Founders of Global Cures
Dr. Akbar Khan with Dr. Vikas Sukhatme and Vidula Sukhatme in Boston (June 2011)
Dr. Vikas Sukhatme is currently the Dean of Emory University School of Medicine. He previously held the title of Chief Academic Officer at BIDMC, Harvard University.
He and his wife Vidula founded GlobalCures, a non-profit medical research organization with a mission to help patients find their best treatment options, share their clinical outcomes and fund clinical trials of promising generic therapies that would not normally be funded. Without such trials, one may never know if the drugs/therapies in question are really working or not. They may work for a while and then fail later. They may work best in conjunction with standard chemotherapy. They may have unexpected side-effects. They may work only in a sub-group of cancer patients. These are the types of questions that will be answered by the clinical trials that GlobalCures will conduct.
Most importantly, physicians will be reluctant to prescribe these therapies without such data, i.e. potential patient benefit versus risk of the therapy. In addition, physicians worry about losing their license or being sued for prescribing un-validated therapies; they may get derided by their colleagues, and they may not understand the rationale for the therapy or its interaction with more conventional therapies in the absence of rigorous data.
One of the targets for research funding is the drug dichloroacetate (DCA). Dr. Sukhatme has already published a paper on a new method of using MRI spectroscopy to rapidly and non-invasively detect if DCA is working within a patient’s body against their cancer:www.ncbi.nlm.nih.gov/pubmed?term=21245941